BioMedNewsBreaks

WednesdayApr 21, 2021 9:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Partnership to Offer Virtual Care for Patients with Diabetes

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is partnering with MediOrbis, a telehealth provider specializing in chronic conditions, to provide remote patient monitoring services to Medicare patients with diabetes. The new virtual care initiative means that Medicare patients who have diabetes and who are eligible can receive convenient virtual care that is covered under their existing Medicare benefits. The telehealth services are delivered by MediOrbis with remote patient monitoring through DarioHealth's AI-powered digital chronic care platform. The announcement noted that the new virtual care program will be available to Dario's approximately 75,000 members with diabetes. Because…

Continue Reading

TuesdayApr 20, 2021 2:39 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Expands Medical Board with Appointment of Triple-Certified Cardiologist

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based and proprietary products for heart and brain health through its subsidiaries, BergametNA(TM) and Ultimate Brain Nutrients(TM), today announced that Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist, has joined Healthy Extracts. According to the update, Dr. Kahn has utilized BergametNA Citrus Bergamot SuperFruit(TM) with thousands of patients and has seen positive cardiovascular benefits and arterial age reversal and flexibility. “We are so excited to welcome Dr. Joel Kahn, one of the few triple-certified cardiologists in the entire U.S., to our Medical Board,” said Duke…

Continue Reading

TuesdayApr 20, 2021 2:07 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes. GNPX has been involved in groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells. The therapy, which involves the diabetes gene therapy candidate GPX-002, is potentially applicable to both type 1…

Continue Reading

TuesdayApr 20, 2021 9:49 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company's…

Continue Reading

TuesdayApr 20, 2021 9:34 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming…

Continue Reading

MondayApr 19, 2021 3:06 pm

BioMedNewsBreaks – GT Biopharma (NASDAQ: GTBP) Releases Q4, Year-End Results, Company Update

GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ…

Continue Reading

MondayApr 19, 2021 12:59 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces FY2020 Business, Financial Results

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is…

Continue Reading

FridayApr 16, 2021 2:42 pm

BioMedNewsBreaks – RYAH Group Inc.’s Products Facilitate Personalized Therapies, Remote Patient Monitoring

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, has created a range of smart devices set to disrupt the future of medicine. RYAH Group, which is on a mission to advance the world’s transition to remote-health solutions, has done precisely that with its remote health platform called RYAH MD. “RYAH MD is a service that allows clinicians to remotely monitor and control patients’ dosing regimens with RYAH’s dose-measuring products. It provides necessary information that doctors can analyze to learn how different dosing variables affect outcomes. RYAH MD allows the doctor to recommend parameters on…

Continue Reading

FridayApr 16, 2021 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market

Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in fluid management systems (https://ibn.fm/rKWZC). As disposal of waste fluids presents a unique set of challenges for every health care facility, Skyline Medical offers a clear solution. Skyline’s patented and FDA-cleared STREAMWAY System is “the new standard in waste fluid management,” automating the collection, measurement and…

Continue Reading

FridayApr 16, 2021 1:24 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the…

Continue Reading